Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $28.38, for a total value of $14,190.00. Following the completion of the transaction, the director now directly owns 73,909 shares of the company’s stock, valued at approximately $2,097,537.42. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Amphastar Pharmaceuticals Trading Down 1.7 %

Shares of AMPH stock traded down $0.49 on Wednesday, hitting $27.80. 717,774 shares of the stock traded hands, compared to its average volume of 442,259. Amphastar Pharmaceuticals, Inc. has a twelve month low of $25.89 and a twelve month high of $53.96. The stock has a market capitalization of $1.32 billion, a PE ratio of 9.27, a PEG ratio of 2.19 and a beta of 0.79. The firm’s 50-day moving average price is $30.78 and its two-hundred day moving average price is $39.63. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Analyst Ratings Changes

Separately, Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in Amphastar Pharmaceuticals in the fourth quarter worth approximately $38,000. Voloridge Investment Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 16.2% in the 4th quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company’s stock valued at $5,326,000 after purchasing an additional 19,991 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of Amphastar Pharmaceuticals by 208.0% during the 4th quarter. Squarepoint Ops LLC now owns 17,664 shares of the company’s stock worth $656,000 after purchasing an additional 11,929 shares during the last quarter. Twinbeech Capital LP purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $1,738,000. Finally, Systematic Financial Management LP acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at about $9,147,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.